研究与开发杂志
开放获取
国际标准期刊号: 2311-3278
国际标准期刊号: 2311-3278
萨维什·辛格
介绍
根据《2017 年全球结核病报告》，印度结核病发病率约为 2800,000 例，占世界结核病病例的四分之一。印度政府于 1992 年在专家委员会的领导下，分阶段为全国启动了修订后的国家结核病控制计划 (RNTCP)。该计划通过纳入新的药物治疗方案——直接观察治疗短期课程（DON'T），帮助以更加管理和分类的形式面对疾病。DOTS 在直接监督下免费提供强制性优质抗结核药物，使该计划更加有效。据联邦卫生和家庭福利部称，2016 年北方邦报告了 26 万例结核病病例。
建议一线治疗使用五种抗结核药物——异烟肼、利福平、乙胺丁醇、吡嗪酰胺和链霉素。但这些治疗的成功率取决于个体的药代动力学。肝毒性是结核病负担重的国家使用抗结核药物造成的严重不良反应。ATD引起的肝毒性的发生影响结核病的治疗，并导致治疗的延误或失败。
材料和方法：
In this prospective study, patients of age will more than 18 years were recruited from the outpatient department or the inpatient facility of the departments of pharmacology and Therapeutics, Clinical haematology, and Respiratory medicine, Gandhi Memorial and Associated Hospitals, King George’s Medical University, Lucknow, Uttar Pradesh, India, between November 2017 to September 2018 after obtaining the ethical clearance from the institute’s ethical committee.
A total no of 100 TB positive patients were recruited in this study. Further, the TB patients were divided into two groups on the basis of anti-TB drugs (ATDs)-induced toxicity. After the treatment with ATDs, 30 pulmonary TB patients developed to the clinical or laboratory-confirmed DIH, whereas 70 patients’ with pulmonary TB did not develop DIH and constituted the controls. Informed written consent was obtained from all the TB patients. Clinical data, such as the disease stage, liver function test, treatment details, and the history of comorbid conditions, were extracted from the patients’ charts.
Results:
ATDIH组和耐受对照组结核病患者的人口统计学资料如表1所示。治疗1个月后，ATDIH组的AST和ALT较耐受对照组显着升高。